Andersson F, Sundin E, Magnusson C, Ramstedt M, Galanti MR (2023) Prevalence of cannabis use among young adults in sweden comparing randomized response technique with a traditional survey. Addiction. https://doi.org/10.1111/add.16219
Bassir Nia A, Medrano B, Perkel C, Galynker I, Hurd YL (2016) Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. J Psychopharmacol 30:1321–1330
Bundeskriminalamt (2023) Polizeiliche kriminalstatistik (pks). In: Bundeskriminalamt (ed)
Bundesministerium für Gesundheit (2023) Entwurf eines gesetzes zum kontrollierten umgang mit cannabis und zur änderung weiterer vorschriften. In:
Bundesministerium für Gesundheit (2023) Mitglieder und versicherte der gesetzlichen krankenversicherung (gkv). In:
Campeny E, Lopez-Pelayo H, Nutt D, Blithikioti C, Oliveras C, Nuno L, Maldonado R, Florez G, Arias F, Fernandez-Artamendi S, Villalbi JR, Sellares J, Ballbe M, Rehm J, Balcells-Olivero MM, Gual A (2020) The blind men and the elephant: Systematic review of systematic reviews of cannabis use related health harms. Eur Neuropsychopharmacol 33:1–35
Article CAS PubMed Google Scholar
Carvalho JV, Souza LS, Moreira EC (2022) Association between cannabis use and suicidal behavior: a systematic review of cohort studies. Psychiatry Res 312:114555
Choi NG, Marti CN, DiNitto DM, Baker SD (2020) Cannabis and synthetic cannabinoid poison control center cases among adults aged 50+, 2009–2019. Clin Toxicol:1–9
Craft S, Dunn M, Vidler D, Officer J, Blagbrough IS, Pudney CR, Henderson G, Abouzeid A, Dargan PI, Eddleston M, Cooper J, Hill SL, Roper C, Freeman TP, Thomas SHL (2022) Trends in hospital presentations following analytically confirmed synthetic cannabinoid receptor agonist exposure before and after implementation of the 2016 uk psychoactive substances act. Addiction 117:2899–2906
Article PubMed PubMed Central Google Scholar
El Haddad R, Lemogne C, Matta J, Wiernik E, Goldberg M, Melchior M, Roquelaure Y, Limosin F, Zins M, Airagnes G (2022) The association of substance use with attaining employment among unemployed job seeking adults: Prospective findings from the french constances cohort. Prev Med 163:107196
European Monitoring Centre for Drugs and Drug Addiction (2023) European drug report 2023: Trends and developments. In:
European Monitoring Centre for Drugs and Drug Addiction (2023) Penalties for drug law offences in europe at a glance. In: European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal
Fischer B, Russell C, Rehm J, Leece P (2018) Assessing the public health impact of cannabis legalization in canada: Core outcome indicators towards an ‘index’ for monitoring and evaluation. J Public Health fdy090-fdy090
Freeman TP, van der Pol P, Kuijpers W, Wisselink J, Das RK, Rigter S, van Laar M, Griffiths P, Swift W, Niesink R, Lynskey MT (2018) Changes in cannabis potency and first-time admissions to drug treatment: a 16-year study in the netherlands. Psychol Med 48:2346–2352
Gahr M, Ziller J, Keller F, Muche R, Preuss UW, Schönfeldt-Lecuona C (2022) Incidence of inpatient cases with mental disorders due to use of cannabinoids in germany: A nationwide evaluation. Eur J Public Health ckab207
Gesundheitsberichterstattung des Bundes (2023) Diagnosedaten der krankenhäuser ab 2000 (eckdaten der vollstationären patienten und patientinnen). Gliederungsmerkmale: Jahre, behandlungs-/wohnort, icd10. In:Statistisches Bundesamt, Bonn
Gunadi C, Shi Y (2022) Association of recreational cannabis legalization with cannabis possession arrest rates in the us. JAMA Netw Open 5:e2244922
Article PubMed PubMed Central Google Scholar
Howell BA, Long JB, Edelman EJ, McGinnis KA, Rimland D, Fiellin DA, Justice AC, Wang EA (2016) Incarceration history and uncontrolled blood pressure in a multi-site cohort. J Gen Intern Med 31:1496–1502
Article PubMed PubMed Central Google Scholar
Lau N, Sales P, Averill S, Murphy F, Sato SO, Murphy S (2015) Responsible and controlled use: older cannabis users and harm reduction. Int J Drug Policy 26:709–718
Article PubMed PubMed Central Google Scholar
Leung J, Chan GCK, Hides L, Hall WD (2020) What is the prevalence and risk of cannabis use disorders among people who use cannabis? A systematic review and meta-analysis. Addict Behav 109:106479
López-Pelayo H, Madero S, Gremeaux L, Rönkä S, Matias J (2022) Synthetic cannabinoids and cannabis: How the patterns of use differ: results from the european web survey on drugs. Int J Mental Health Addict. https://doi.org/10.1007/s11469-022-00919-6
Manthey J, Freeman TP, Kilian C, López-Pelayo H, Rehm J (2021) Public health monitoring of cannabis use in europe: Prevalence of use, cannabis potency, and treatment rates. Lancet Regional Health Europe 10:100227
Article PubMed PubMed Central Google Scholar
Manthey J, Hayer T, Jacobsen B, Kalke J, Klinger S, Rehm J, Rosenkranz M, Verthein U, Wirth M, Armstrong M, Myran D, Pacula R, Queirolo R, Zobel F (2023) Effects of legalizing cannabis. In:Bundesministerium für Gesundheit
Meier MH, Caspi A, Knodt A, Hall W, Ambler A, Harrington H, Hogan S, Houts MR, Poulton R, Ramrakha S, Hariri AR, Moffitt TE (2022) Long-term cannabis use and cognitive reserves and hippocampal volume in midlife. Am J Psychiatry. https://doi.org/10.1176/appi.ajp.2021.21060664
Article PubMed PubMed Central Google Scholar
Mennis J, McKeon TP, Stahler GJ (2023) Recreational cannabis legalization alters associations among cannabis use, perception of risk, and cannabis use disorder treatment for adolescents and young adults. Addict Behav 138:107552
Mennis J, Stahler GJ, McKeon TP (2021) Young adult cannabis use disorder treatment admissions declined as past month cannabis use increased in the U.S.: an analysis of states by year, 2008–2017. Addict Behav 107049
National Academies of Sciences E, and Medicine (2017) The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. In: National Academies Press (US), Washington, DC
Oomen PE, Schori D, Tögel-Lins K, Acreman D, Chenorhokian S, Luf A, Karden A, Paulos C, Fornero E, Gerace E, Koning RPJ, Galindo L, Smit-Rigter LA, Measham F, Ventura M (2022) Cannabis adulterated with the synthetic cannabinoid receptor agonist mdmb-4en-pinaca and the role of european drug checking services. Int J Drug Policy 100:103493
Orth B, Merkel C (2022) Der substanzkonsum jugendlicher und junger erwachsener in deutschland. Ergebnisse des alkoholsurveys 2021 zu alkohol, rauchen, cannabis und trends. In: BZgA-Forschungsbericht. Bundeszentrale für gesundheitliche Aufklärung, Köln
Perkonigg A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R, Wittchen HU (2008) The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction 103:439–449; discussion 450–431
Petrilli K, Ofori S, Hines L, Taylor G, Adams S, Freeman TP (2022) Association of cannabis potency with mental ill health and addiction: a systematic review. Lancet Psychiatry 9:736–750
Piontek D, Gomes de Matos E, Atzendorf J, Kraus L (2016) Kurzbericht epidemiologischer suchtsurvey 2015. In: Tabellenband: Konsum illegaler Drogen, multiple Drogener‐
fahrung und Hinweise auf klinisch relevanten Drogenkonsum nach Geschlecht und Alter im Jahr 2015. IFT Institut für Therapieforschung, München
R Core Team (2023) R: A language and environment for statistical computing. In: R Foundation for Statistical Computing, Vienna, Austria
Rauschert C, Möckl J, Seitz NN, Wilms N, Olderbak S, Kraus L (2022) The use of psychoactive substances in germany-findings from the epidemiological survey of substance abuse 2021. Deutsches Arzteblatt Int 119:527–534
Rauschert C, Möckl J, Wilms N, Hoch PDE, Kraus PDL, Olderbak DS (2023) Kurzbericht epidemiologischer suchtsurvey 2021. In: Tabellenband: (problematischer) Konsum illegaler Drogen und multiple Drogenerfahrung nach Geschlecht und Alter im Jahr 2021. Munich
Redmond N, Hicks LS, Cheng DM, Allensworth-Davies D, Winter MR, Samet JH, Saitz R (2014) Association of recent incarceration with traumatic injury, substance use-related health consequences, and health care utilization. J Addict Med 8:66–72
Article PubMed PubMed Central Google Scholar
Rhee TG, Rosenheck RA (2022) Admissions to substance use treatment facilities for cannabis use disorder, 2000–2017: Does legalization matter? Am J Addict 31:423–432
Robinson T, Ali MU, Easterbrook B, Hall W, Jutras-Aswad D, Fischer B (2022) Risk-thresholds for the association between frequency of cannabis use and the development of psychosis: a systematic review and meta-analysis. Psychol Med 1–11
Schmidt K, Tseng I, Phan A, Fong T, Tsuang J (2020) A systematic review: adolescent cannabis use and suicide. Addict Disord Treat 19:146–151
Schwarzkopf L, Künzel J, Murawski M, Specht S (2022) Suchthilfe in deutschland 2021. In: Jahresbericht der deutschen Suchthilfestatistik (DSHS). Institut für Therapieforschung, München
Seitz N-N, Lochbühler K, Atzendorf J, Rauschert C, Tim PG, Kraus L (2019) Trends in substance use and related disorders. Deutsches Aerzteblatt Online 116:585–591
Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM, Spry E, Toumbourou JW, Degenhardt L, Swift W, Coffey C, Tait RJ, Letcher P, Copeland J, Mattick RP (2014) Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry 1:286–293
United Nations Office on Drugs and Crime (2023) World drug report 2023. In: United Nations publication
Yang PK, Odom EC, Patel R, Loustalot F, Coleman King S (2022) Nonmedical marijuana use and cardiovascular events: A systematic review. Public Health Rep 137:62–71
Zhu Y, Greenfield TK, Ye Y, Williams E, Kerr WC (2024) Life-course accumulated cannabis use and recent cannabis-related problems in the washington panel survey. Addict Behav 152:107957
留言 (0)